A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Nuvectis Pharma, Inc.
AdventHealth
University of Pennsylvania
Plexium, Inc.
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Elevation Oncology
Rondo Therapeutics
University of Chicago
Novartis
Nuvectis Pharma, Inc.
University of Pennsylvania
Memorial Sloan Kettering Cancer Center
Centre Hospitalier Universitaire Vaudois
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Carisma Therapeutics Inc
Astellas Pharma Inc
Astellas Pharma Inc
Pfizer
Advaxis, Inc.
AO GENERIUM
Adaptimmune
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Cantargia AB
Blueprint Medicines Corporation
Karyopharm Therapeutics Inc
Novartis
Daiichi Sankyo
National Institutes of Health Clinical Center (CC)
Checkpoint Therapeutics, Inc.
Novartis
Northwell Health
AbGenomics B.V Taiwan Branch
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Cedars-Sinai Medical Center
Novartis
University of Utah
H. Lee Moffitt Cancer Center and Research Institute
Navidea Biopharmaceuticals
University of Utah
University of Rochester
Janssen Research & Development, LLC
UbiVac
National Institutes of Health Clinical Center (CC)
Providence Health & Services
National Institutes of Health Clinical Center (CC)